Antivirals: current state of the art

被引：25

作者：

De Clercq, Erik ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

FUTURE VIROLOGY | 2008年 / 3卷 / 04期

关键词：

approved antiviral; CMV; experimental antiviral; HBV; HCV; HIV; HSV; influenza virus; poxvirus; VZV;

D O I：

10.2217/17460794.3.4.393

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Most of the antiviral agents that have been approved, and are currently used in the treatment of virus infections, are targeted at HIV, HBV, herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV) and HCV or influenza virus. Additional compounds for HIV, HBV, HSV, VZV, CMV, HCV, influenza virus and several other viral infections, for example poxvirus (e.g., variola, vaccinia and monkeypox), respiratory syncytial virus, hemorrhagic fever virus (e.g., Lassa, Rift Valley and Ebola) and enterovirus (e.g., polio, Coxsackie and echo), are still in the experimental stage, that is, under clinical or preclinical development.

引用

页码：393 / 405

页数：13

共 51 条

[1] Susceptibilities of several clinical Varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides [J].

Andrei, G ;

Sienaert, R ;

McGuigan, C ;

De Clercq, E ;

Balzarini, J ;

Snoeck, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :1081-1086

[2]

Baumeister Judith, 2007, Antiviral Chemistry & Chemotherapy, V18, P35

[3] Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293 [J].

Betz, UAK ;

Fischer, R ;

Kleymann, G ;

Hendrix, M ;

Rübsamen-Waigmann, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1766-1772

[4] Antiviral drugs for cytomegalovirus diseases [J].

Biron, Karen K. .

ANTIVIRAL RESEARCH, 2006, 71 (2-3) :154-163

[5]

Biswas Subhajit, 2007, Antiviral Chemistry & Chemotherapy, V18, P13

[6] Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency 2 of 10 recent clinical isolates of HSV-1 [J].

Biswas, Subhajit ;

Smith, Christopher ;

Field, Hugh J. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (02) :274-279

[7] The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1 [J].

Biswas, Subhajit ;

Jennens, Lyn ;

Field, Hugh J. .

ANTIVIRAL RESEARCH, 2007, 75 (01) :30-35

[8] Interferons at age 50: past, current and future impact on biomedicine [J].

Borden, Ernest C. ;

Sen, Ganes C. ;

Uze, Gilles ;

Silverman, Robert H. ;

Ransohoff, Richard M. ;

Foster, Graham R. ;

Stark, George R. .

NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (12) :975-990

[9] 3-deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice [J].

Bray, M ;

Raymond, JL ;

Geisbert, T ;

Baker, RO .

ANTIVIRAL RESEARCH, 2002, 55 (01) :151-159

[10] A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products [J].

Buerger, I ;

Reefschlaeger, J ;

Bender, W ;

Eckenberg, P ;

Popp, A ;

Weber, O ;

Graeper, S ;

Klenk, HD ;

Ruebsamen-Waigmann, H ;

Hallenberger, S .

JOURNAL OF VIROLOGY, 2001, 75 (19) :9077-9086

← 1 2 3 4 5 6 →